{
    "clinical_study": {
        "@rank": "48525", 
        "acronym": "QTVIE", 
        "arm_group": [
            {
                "arm_group_label": "\u2022 HIV positive subjects receiving antiretroviral regimen"
            }, 
            {
                "arm_group_label": "\u2022 HIV negative subjects from the pre-admission surgical clinic"
            }
        ], 
        "biospec_descr": {
            "textblock": "10 mL whole blood in a purple Vacutainer EDTA tube"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This is a unicentric, two cohorts, observational transversal study.\n\n      The purpose of this study is to compare the QT/QTc intervals of HIV positive subjects\n      receiving an antiretroviral therapy and those without HIV in an ambulatory care setting."
        }, 
        "brief_title": "Comparison of the QT/QTc Interval Between an Outpatient HIV-Infected Population on Antiretroviral Therapy and Two Large HIV-Negative Cohorts", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "QT and Corrected QT Intervals Prolongation in HIV Positive Subjects Treated With an Antiretroviral Regimen", 
        "condition_browse": {
            "mesh_term": "HIV Seropositivity"
        }, 
        "detailed_description": {
            "textblock": "Primary objective:\n\n      The primary objective is to compare the QT/QTc intervals of HIV positive subjects treated\n      with antiretroviral therapy and followed at the ambulatory HIV clinic and the QT/QTc\n      intervals of :\n\n        1. an outpatient HIV negative population from the same health center pre-admission one-day\n           surgical clinic.\n\n        2. the large HIV-free korean population studied in the ECG-ViEW database.\n\n      Secondary objectives :\n\n        -  Evaluate the prevalence of QTc interval prolongation in the outpatient HIV positive\n           population comparatively to the two HIV negative outpatient populations available from\n           the one-day surgical clinic and the ECG-ViEW database.\n\n        -  Evaluate risk factors associated with QTc interval prolongation in the outpatient HIV\n           positive population compared to the outpatient HIV negative population and the\n           population studied in the ECG-ViEW database.\n\n        -  Compare the QT/QTc intervals and the prevalence of QTc interval prolongation of the\n           outpatient HIV positive population currently on an antiretroviral regimen including a\n           protease inhibitor versus those on an antiretroviral regimen without protease\n           inhibitor.\n\n        -  Compare the QT/QTc intervals among the outpatient HIV positive population treated with\n           a protease inhibitor, in regard to the presence or the absence of certain genetic\n           polymorphisms that may influence pharmacokinetic aspects of protease inhibitors."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age eligible for study : 18-65 years old inclusively\n\n          -  Gender  eligible for study : Both\n\n        Exclusion Criteria:\n\n          -  Hospitalised at the moment of recruitment\n\n          -  AIDS status\n\n             o Opportunistic infections acquired in the last 30 days before the date of\n             recruitment\n\n          -  Age < 18 years old and > 65 years old\n\n          -  Follow-up care in an oncology clinic\n\n          -  Dialysis during the study period\n\n          -  Pregnancy\n\n          -  Without antiretroviral therapy\n\n          -  History of a myocardial infarction in the 3 weeks preceding recruitment\n\n          -  Have a pacemaker\n\n          -  Diagnosed with bundle branch block on ECG\n\n          -  Principal follow-up care outside of the CHUM HIV clinic\n\n          -  Refusal to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study is being conducted within the Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al\n        (CHUM). The recruited population was identified from the CHUM ambulatory care HIV clinic\n        and an ECG registry composed of outpatient HIV negative subjects who were scheduled for a\n        one-day surgery. The HIV positive outpatients on antiretroviral therapy will be recruited\n        prospectively from March 2013 through August 2013. The outpatient HIV negative cohort will\n        be recruited retrospectively according to a 10:1 ratio."
            }
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01824628", 
            "org_study_id": "CE12.316"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montr\u00e9al", 
                    "country": "Canada", 
                    "state": "Quebec"
                }, 
                "name": "Unit\u00e9 Hospitali\u00e8re de Recherche et d'Enseignement et de Soins sur le Sida (UHRESS) ; Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM)"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "2", 
        "official_title": "Comparaison Des Intervalles QT/QTc Entre Une Population HIV Positive Ambulatoire Sous th\u00e9rapie antir\u00e9trovirale et Une Population Ambulatoire HIV n\u00e9gative", 
        "overall_official": {
            "affiliation": "Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al", 
            "last_name": "Jacques Turgeon, B. Pharm., M. Sc., Ph. D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The QT/QTc intervals are determined by a 50 mm/s 12-leads ECG in the outpatient HIV positive population. The ECG is conducted in the morning, between 8:00 and 12:00 to limit the circadian variation.\nFor the control group, the QT/QTc intervals are assessed through a registry of outpatient HIV negative subjects who had had a standard 12-leads ECG done in pre-admission one-day surgery clinic.\nIn both groups, the corrected QT interval is calculated with the Bazett's formula and the Fridericia's formula.", 
            "measure": "QT and corrected QT (QTc) intervals determined by a 12-leads ECG", 
            "safety_issue": "No", 
            "time_frame": "Day 0 = Day 1 - This is a transversal study."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01824628"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Compare the QTc intervals calculated with the Bazett's formula and the Fridericia's formula in both study groups in order to determine the prevalence of QTc interval prolongation. The QTc interval is considered to be prolonged if it exceeds 430 ms in women and 450 ms in men.", 
                "measure": "Prevalence of QTc interval prolongation in both study groups", 
                "safety_issue": "No", 
                "time_frame": "Day 0 = Day 1 - This is a transversal study."
            }, 
            {
                "description": "A predetermined questionnaire is filled for each of the study subjects in order to assess factors associated with an increased QTc interval prolongation. This contains demographic information (age, sex, ethnicity...), known health issues (cardiovascular diseases, diabetes, liver diseases...), concomitant drugs, etc.", 
                "measure": "To assess risk factors of QTc interval prolongation in both study groups", 
                "safety_issue": "No", 
                "time_frame": "Day 0 = Day 1 - This is a transversal study."
            }, 
            {
                "description": "Compare the QTc intervals calculated with the Bazett's formula and the Fridericia's formula between outpatient HIV positive subjects treated with a protease inhibitor (PI) based antiretroviral regimen and those treated with an antiretroviral regimen without PI. The QTc interval is considered to be prolonged if it exceeds 430 ms in women and 450 ms in men.", 
                "measure": "Prevalence of QT/QTc intervals prolongation and associated risk factors among outpatient HIV subjects", 
                "safety_issue": "No", 
                "time_frame": "Day 0 = Day 1 - This is a transversal study."
            }, 
            {
                "description": "A blood sample of each subject treated with a PI is analyzed in the laboratory in order to determine whether certain genetic polymorphisms influence on the metabolism of the drug, thus causing a QTc interval prolongation or not.", 
                "measure": "Evaluate the influence of genetic polymorphisms on PI's pharmacokinetic metabolisms in outpatient HIV positive subjects treated with a PI", 
                "safety_issue": "No", 
                "time_frame": "Day 0 = Day 1 - This is a transversal study"
            }
        ], 
        "source": "Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}